Bluebird’s Zynteglo Approval Kicks Off Commercial Operations
Beta-Thalassemia Gene Therapy’s List Price Is $2.8m
Bluebird bio’s Tom Klima told Scrip launch preparations are well under way, including negotiations with payers on outcomes-based reimbursement agreements.
You may also be interested in...
The company said when Zynteglo was approved for beta-thalassemia that its launch would lay the groundwork for its sickle cell gene therapy Lyfgenia, and the strategy is paying off so far with a fast ramp-up.
When Zynteglo was approved for beta-thalassemia, bluebird said launch would lay groundwork for sickle cell gene therapy Lyfgenia. The strategy is paying off so far with a fast ramp-up. Outcomes-based contracts for Lyfgenia give payers rebate based on hospitalizations over a three-year period.
The two first-ever therapies to offer sickle cell disease patients the possibility of lifetime relief from painful vaso-occlusive events or crises are hitting the market, but face tough commercial challenges.